KAUST researchers have discovered how sea anemones recycle nitrogen waste, allowing them to thrive in nutrient-poor ocean environments. The study used laser microdissection and single-cell RNA-sequencing to analyze tissue-specific gene expression in Aiptasia. They found that anemones distribute glucose received from symbionts across tissues to recycle nitrogen waste. Why it matters: This research enhances understanding of coral reef ecosystems and their resilience, which is particularly relevant for Red Sea biodiversity and Saudi Arabia's environmental efforts.
KAUST researchers are exploring the link between nutrition and brain-energy metabolism to address cognitive decline, dementia, and Alzheimer’s disease. Dr. Pierre Magistretti and Dr. Johannes le Coutre are collaborating on ways to merge brain-energy metabolism research into the field of nutrition. They published an article entitled “Goals in Nutrition Science 2015-2020” in the journal Frontiers in Nutrition. Why it matters: This research could lead to nutritional interventions to hinder or prevent cognitive decline, offering a new approach beyond traditional drug treatments.
KAUST researchers collaborated to identify molecular pathways for plant biofortification of vitamin A. A KAUST group demonstrated high pressure conversion of carbon dioxide into useful products. Another team designed a biosensor using metal oxide transistors to detect glucose in saliva. Why it matters: These projects highlight KAUST's contributions to biotechnology, environmental sustainability, and healthcare through advanced materials and molecular techniques.
MBZUAI researchers co-led a study published in Nature demonstrating that GluFormer, an AI foundation model trained on continuous glucose monitoring (CGM) data, more accurately predicts long-term diabetes and cardiovascular risk than current clinical standards. GluFormer, built on a transformer architecture and trained using NVIDIA AI infrastructure on over 10 million CGM measurements, forecasts individual health risks using short-term glucose dynamics. In a 12-year follow-up, the model captured 66% of new-onset diabetes cases and 69% of cardiovascular-death events in its highest-risk group, outperforming established CGM-derived metrics across 19 external cohorts. Why it matters: The development of GluFormer represents a significant advancement in personalized healthcare, enabling proactive and individualized health strategies through the analysis of dynamic glucose data.
KAUST Discovery highlights the contributions of Magistretti to the field of neuroenergetics. His research explores the cellular and molecular basis of brain energy metabolism and brain imaging. Magistretti's group discovered mechanisms underlying the coupling between neuronal activity and energy consumption, revealing the role of astrocytes. Why it matters: Understanding brain energy metabolism and the role of glial cells can advance brain imaging techniques and our understanding of neuronal processes.
This paper introduces a method for automatically designing convolutional neural network (CNN) architectures tailored for diabetic retinopathy (DR) diagnosis using fundus images. The approach uses k-medoid clustering, PCA, and inter/intra-class variations to optimize CNN depth and width. Validated on datasets including a local Saudi dataset and Kaggle benchmarks, the custom-designed models outperform pre-trained CNNs with fewer parameters.
KAUST researchers discovered that the red algae strain Galdieria yellowstonesis can convert sugars from chocolate-processing waste into C-phycocyanin, a valuable blue pigment. The study found that high levels of carbon dioxide promote Galdieria growth, and the resulting phycocyanin was deemed food-safe by the U.S. FDA. Mars supported the research by providing chocolate samples. Why it matters: This research offers a sustainable method for waste management and contributes to a circular economy in the region, with potential applications in food, cosmetics, and pharmaceuticals.
KAUST and Saudi healthtech company amplifAI health have signed an MoU to develop a new disease detection system. The system will combine amplifAI's AI technology with KAUST's HyplexTM hyperspectral imaging, initially for diabetic foot complications. Clinical trials are planned, with aims to reduce amputations and save Saudi Arabia over 2 billion Riyals annually. Why it matters: This partnership showcases the potential of combining Saudi AI and advanced imaging technologies to address pressing healthcare challenges in the region, particularly diabetes.